Tribatens 40/5/25 Mg - 30 Tap

Tribatens 40/5/25 Mg - 30 Tap

Description:

Tribatens 40/5/25 mg is a prescription anti-hypertensive medicine combining three active ingredients: olmesartan, amlodipine, and hydrochlorothiazide in one film-coated tablet. It is designed for adult patients who require combination therapy to effectively control high blood pressure (hypertension) and reduce cardiovascular risk. By targeting different mechanisms that regulate blood pressure, Tribatens helps lower and maintain blood pressure within a healthy range, supporting heart, brain, and kidney protection when used as directed by a physician.

Indications:

• Treatment of essential hypertension (high blood pressure) in adults.
• Management of patients whose blood pressure is not adequately controlled with dual therapy (e.g., olmesartan plus amlodipine, or olmesartan plus hydrochlorothiazide, or amlodipine plus hydrochlorothiazide).
• Patients who are already stabilized on the individual components taken separately and wish to switch to a single tablet for convenience and improved compliance.
• Helps reduce the risk of hypertension-related complications such as stroke, heart attack, and kidney damage when used as part of a comprehensive cardiovascular risk reduction plan.

Active Ingredients / Key Components:

• Olmesartan medoxomil – 40 mg per film-coated tablet (angiotensin II receptor blocker – ARB).
• Amlodipine besylate – 5 mg per film-coated tablet (dihydropyridine calcium channel blocker).
• Hydrochlorothiazide – 25 mg per film-coated tablet (thiazide diuretic).
• Other inactive ingredients (excipients, film-coating agents, stabilizers) are present but detailed composition is not available in the provided information.

Dosage & Administration / How to Use:

• Tribatens 40/5/25 mg is for oral use only and should be taken exactly as prescribed by your physician.
• Usual dose: one tablet once daily, preferably at the same time each day. Do not exceed the prescribed dose.
• Can be taken with or without food; swallow the tablet whole with a sufficient amount of water. Do not crush or chew.
• If switching from separate tablets of olmesartan, amlodipine, and hydrochlorothiazide, your doctor will determine the appropriate equivalent dose.
• In patients with renal or hepatic impairment, elderly patients, or those on other antihypertensive medicines, the dose may need adjustment as directed by the physician.
• If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed tablet.
• Continue taking Tribatens regularly even if you feel well, as high blood pressure often has no symptoms. Do not stop treatment without consulting your doctor.

Clinical Benefits:

• Provides triple antihypertensive action by combining an ARB, a calcium channel blocker, and a thiazide diuretic in one tablet for enhanced blood pressure control.
• Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to relaxation of blood vessels and reduction of blood pressure.
• Amlodipine acts directly on vascular smooth muscle to produce peripheral arterial vasodilation, lowering peripheral vascular resistance and blood pressure.
• Hydrochlorothiazide increases excretion of sodium and water by inhibiting sodium reabsorption in the distal renal tubules, helping reduce blood volume and blood pressure.
• Single-tablet regimen improves treatment convenience and may enhance patient adherence compared to taking multiple separate medicines.
• Supports long-term protection of vital organs such as heart, brain, and kidneys when used as part of a comprehensive hypertension management plan including lifestyle modifications.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to olmesartan, amlodipine, hydrochlorothiazide, other sulfonamide-derived drugs, or any component of the formulation.
• Contraindicated during pregnancy. Drugs acting on the renin–angiotensin system (such as ARBs) can cause injury and death to the developing fetus. If pregnancy is detected, discontinue Tribatens as soon as possible.
• Not recommended during breastfeeding unless clearly needed and only under strict medical supervision.
• Contraindicated in severe renal impairment, anuria, or severe hepatic impairment, and in patients with refractory hypokalemia, hypercalcemia, or symptomatic hyperuricemia/gout related to thiazide use.
• Use with caution in patients with renal impairment, hepatic impairment, heart failure, aortic stenosis, hypertrophic cardiomyopathy, electrolyte disturbances (such as low potassium, sodium, or magnesium), diabetes, gout, or a history of angioedema.
• May cause symptomatic hypotension, especially in volume-depleted patients (e.g., on high-dose diuretics, low-salt diet, diarrhea, or vomiting). Start under medical supervision.
• Hydrochlorothiazide may increase blood glucose, uric acid, and lipids; periodic monitoring is recommended in diabetic and gout patients.
• Monitor kidney function, serum electrolytes (potassium, sodium), and blood pressure regularly during treatment.
• May interact with other medicines such as lithium, NSAIDs, other antihypertensives, potassium-sparing diuretics, potassium supplements, certain antidiabetics, and drugs affecting CYP3A4. Inform your doctor about all medicines and supplements you are taking.
• May cause dizziness or fatigue; use caution when driving or operating machinery until you know how the medicine affects you.
• Consult your doctor before use if pregnant, nursing, taking medications, or have medical conditions such as kidney disease, liver disease, heart failure, diabetes, gout, or electrolyte imbalance.
• Not intended to diagnose, treat, cure, or prevent any disease outside its approved medical indications.
• Keep out of reach of children.

Side Effects:

• Common side effects may include dizziness, headache, fatigue, flushing, ankle or leg swelling (peripheral edema), palpitations, and mild gastrointestinal disturbances such as nausea or abdominal discomfort.
• Hydrochlorothiazide-related effects may include increased urination, changes in electrolytes (low potassium, low sodium), increased uric acid (which may trigger gout), and mild increases in blood glucose or cholesterol.
• Less common but serious side effects can include severe hypotension, kidney function deterioration, severe electrolyte imbalance, allergic reactions, angioedema (swelling of face, lips, tongue, or throat), chest pain, or arrhythmias.
• Stop the medicine and seek immediate medical attention if you experience difficulty breathing, severe dizziness or fainting, swelling of the face or throat, severe abdominal pain, yellowing of the skin or eyes, or unusual muscle weakness or cramps.
• Report any persistent, bothersome, or unexpected side effects to your doctor or pharmacist.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Form: Film-coated tablet.
• Strength per tablet: olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 25 mg.
• Pack size: 30 film-coated tablets – typically a 1-month supply at one tablet daily, as directed by the physician.
• Route of administration: Oral.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.